Biotech Values

[lumpy9200]

Lazard upgrades AMLN (only to a hold, but...)

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070413:MTFH74319_2...

April 13 (Reuters) -

Current Prior Rating Hold Sell


--Lazard Capital Markets said Byetta, which is Amylin and Eli Lilly and Co.'s (LLY.N: Quote, Profile , Research) treatment for type 2 diabetes, may enjoy modest growth during the next six to 12 months.

--The impact of Merck & Co. Inc.'s (MRK.N: Quote, Profile , Research) rival diabetes drug Januvia is expected to dissipate over the next six to nine months, it added.

--Shares of the company rose by $1.19, about 3 percent, to $40.14 in morning trade on the Nasdaq. (Reporting by Aditi Samajpati in Bangalore)